Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children with Achondroplasia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia
- Focus Registrational; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 21 Jun 2022 According to a BioMarin Pharmaceutical media release, the Ministry of Health, Labor and Welfare (MHLW) in Japan granted approval of the registration of VOXZOGO (vosoritide) for injection, indicated for the treatment of achondroplasia in children of all ages, whose growth plates are not closed.
- 23 Feb 2022 Updated results published in the BioMarin Pharmaceutical financial media release.
- 19 Nov 2021 According to a USA Food and Drug Administration media release, This FDA approval of Voxzogo is under the accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need, based on a surrogate or intermediate clinical endpoint.